Skip to search formSkip to main contentSkip to account menu

IPI-145

Known as: PI3K delta/gamma Inhibitor IPI-145 
An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Background: Duvelisib, a potent inhibitor of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K) is being developed as a… 
2014
2014
Introduction: Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are uncommon lymphoid malignancies. Approved… 
2014
2014
Phosphoinositide 3-kinases g and d (PI3K g and PI3K d ) are expressed in rheumatoid arthritis (RA) synovium and regulate innate… 
Review
2014
Review
2014
Purpose of review The phosphoinositide 3-kinase (PI3K) pathway, with downstream targets including Akt and mammalian target of… 
2013
2013
7070 Background: Phosphoinositide-3-kinases (PI3Ks) are pivotal in cell signaling and regulate a variety of cellular functions… 
2013
2013
Introduction IPI-145 is an oral, potent PI3K-δ,γ inhibitor currently in development for the treatment of hematologic (heme… 
2013
2013
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma (NHL). Despite aggressive… 
2013
2013
Phosphoinositide-3 kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell… 
2013
2013
Phosphoinositide-3 kinases (PI3Ks) are key cellular signaling proteins that act as a central node, relaying signals from cell…